BARD1 Life Sciences

BARD1 Life Sciences Ltd (ASX:BD1) (BARD1 or the Company) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers.

Latest Media Releases

BARD1 Life Sciences Appoints New CSO

16/09/2021 09:56:00

BARD1 appoints eminent medical researcher Dr Greg Rice as Chief Scientific Officer (CSO) to accelerate the commercial development of its diagnostic tests Dr Rice has extensive commercial and acad…

Latest News